• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌患者接种新型冠状病毒疫苗后的体液免疫反应。

Humoral Response after SARS-CoV-2 Vaccination in Prostate Cancer Patients.

作者信息

Błaszczuk Agata, Sikora Dominika, Kiś Jacek, Stępień Ewa, Drop Bartłomiej, Polz-Dacewicz Małgorzata

机构信息

SARS Laboratory, Department of Virology, Medical University of Lublin, 20-093 Lublin, Poland.

1st Clinical Military Hospital with Outpatient Clinic in Lublin, 20-049 Lublin, Poland.

出版信息

Vaccines (Basel). 2023 Mar 30;11(4):770. doi: 10.3390/vaccines11040770.

DOI:10.3390/vaccines11040770
PMID:37112682
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10144447/
Abstract

Cancer is an important public health problem. Prostate cancer is one of the most common cancers among men. In Poland, the incidence of this type of cancer is constantly growing. Considering the appearance of a new coronavirus in December 2019 (SARS-CoV-2) and the fact that oncology patients, including those with prostate cancer, are particularly vulnerable to infection, it is recommended to get vaccinated against COVID-19. In our study, we determined the level and prevalence of antibodies against SARS-CoV-2 IgG in patients with prostate cancer compared to the control group and whether the patients' ages affected the level of antibodies. PCa patients and controls were divided into two age groups: 50-59 years and 60-70 years. We also analyzed the level of antibodies in patients belonging to the relevant risk groups for prostate cancer (the European Society of Urology risk group classification of prostate cancer). For the study, we used the Microblot-Array COVID-19 IgG test to detect antibodies against the three main SARS-CoV-2 antigens: NCP, RBD, and S2. Our results showed that prostate cancer patients had significantly lower levels of anti-SARS-CoV-2 IgG antibodies compared to controls. In addition, age also affected the decrease in the number of IgG antibodies. The level of antibodies in the intermediate/high-risk group was lower compared to the low-risk group.

摘要

癌症是一个重要的公共卫生问题。前列腺癌是男性中最常见的癌症之一。在波兰,这种类型癌症的发病率在持续上升。鉴于2019年12月新型冠状病毒(SARS-CoV-2)的出现,以及包括前列腺癌患者在内的肿瘤患者特别容易感染这一事实,建议接种新冠疫苗。在我们的研究中,我们测定了前列腺癌患者与对照组相比针对SARS-CoV-2 IgG的抗体水平和流行率,以及患者年龄是否影响抗体水平。前列腺癌患者和对照组被分为两个年龄组:50 - 59岁和60 - 70岁。我们还分析了属于前列腺癌相关风险组(欧洲泌尿外科学会前列腺癌风险组分类)患者的抗体水平。在这项研究中,我们使用微印迹阵列新冠病毒IgG检测来检测针对三种主要SARS-CoV-2抗原:核衣壳蛋白(NCP)、受体结合域(RBD)和刺突蛋白S2亚基(S2)的抗体。我们的结果显示,与对照组相比,前列腺癌患者的抗SARS-CoV-2 IgG抗体水平显著更低。此外,年龄也影响了IgG抗体数量的减少。中/高风险组的抗体水平低于低风险组。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff7/10144447/9c39aaeef528/vaccines-11-00770-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff7/10144447/737e7542e583/vaccines-11-00770-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff7/10144447/2518c980f5b7/vaccines-11-00770-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff7/10144447/9c39aaeef528/vaccines-11-00770-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff7/10144447/737e7542e583/vaccines-11-00770-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff7/10144447/2518c980f5b7/vaccines-11-00770-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/eff7/10144447/9c39aaeef528/vaccines-11-00770-g003.jpg

相似文献

1
Humoral Response after SARS-CoV-2 Vaccination in Prostate Cancer Patients.前列腺癌患者接种新型冠状病毒疫苗后的体液免疫反应。
Vaccines (Basel). 2023 Mar 30;11(4):770. doi: 10.3390/vaccines11040770.
2
Antibodies to NCP, RBD and S2 SARS-CoV-2 in Vaccinated and Unvaccinated Healthcare Workers.接种疫苗和未接种疫苗的医护人员体内针对新型冠状病毒肺炎(NCP)、受体结合域(RBD)和刺突蛋白2(S2)的抗体
Vaccines (Basel). 2022 Jul 22;10(8):1169. doi: 10.3390/vaccines10081169.
3
Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.2021 年 5 月波兰人群中对 SARS-CoV-2 具有免疫力的隐匿人群。
PLoS One. 2022 Feb 3;17(2):e0253638. doi: 10.1371/journal.pone.0253638. eCollection 2022.
4
Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?接种 COVID-19 疫苗后,人乳中能否检测到 SARS-CoV-2 抗体?
J Pediatric Infect Dis Soc. 2022 Apr 30;11(4):126. doi: 10.1093/jpids/piac024.
5
Systemic COVID-19 Vaccination Enhances the Humoral Immune Response after SARS-CoV-2 Infection: A Population Study from a Hospital in Poland Criteria for COVID-19 Reimmunization Are Needed.全身性新冠病毒疫苗接种可增强感染新冠病毒后的体液免疫反应:一项来自波兰一家医院的人群研究 需要制定新冠病毒再次免疫的标准。
Vaccines (Basel). 2022 Feb 19;10(2):334. doi: 10.3390/vaccines10020334.
6
Early humoral response to COVID-19 vaccination in patients living with obesity and diabetes in France. The COVPOP OBEDIAB study with results from the ANRS0001S COV-POPART cohort.法国肥胖和糖尿病患者对 COVID-19 疫苗接种的早期体液反应。COVPOP OBEDIAB 研究结果来自 ANRS0001S COV-POPART 队列。
Metabolism. 2023 May;142:155412. doi: 10.1016/j.metabol.2023.155412. Epub 2023 Jan 31.
7
Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.日本对 BNT162b2 疫苗的抗体反应:通过测量针对 SARS-CoV-2 受体结合域的 IgG 抗体来监测疫苗效力。
Microbiol Spectr. 2022 Feb 23;10(1):e0118121. doi: 10.1128/spectrum.01181-21. Epub 2022 Jan 19.
8
[Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].[对感染新冠病毒疾病并接种新冠疫苗的医护人员的新冠病毒特异性体液免疫和细胞免疫值的调查]
Mikrobiyol Bul. 2022 Jul;56(3):480-492. doi: 10.5578/mb.20229708.
9
Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays.采用微阵列和其他 12 种免疫分析法评估急性 SARS-CoV-2 感染中 S1、S2 和 NCP 特异性 IgM、IgA 和 IgG 抗体的动力学。
J Clin Microbiol. 2021 Apr 20;59(5). doi: 10.1128/JCM.02890-20.
10
Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.化学发光免疫分析检测疫苗接种和康复 COVID-19 队列中中和抗体和结合抗体的纵向分布。
Immun Inflamm Dis. 2022 Jun;10(6):e612. doi: 10.1002/iid3.612.

本文引用的文献

1
The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose.癌症患者对突破性 COVID-19 感染或第四剂 BNT162b2 疫苗的体液反应。
Oncologist. 2023 Apr 6;28(4):e225-e227. doi: 10.1093/oncolo/oyad003.
2
Impact of Immune Cells in the Tumor Microenvironment of Prostate Cancer Metastasis.免疫细胞在前列腺癌转移肿瘤微环境中的作用
Life (Basel). 2023 Jan 26;13(2):333. doi: 10.3390/life13020333.
3
Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave.
奥密克戎变异株流行期间 SARS-CoV-2 突破性感染和再感染的传染性。
Nat Med. 2023 Feb;29(2):358-365. doi: 10.1038/s41591-022-02138-x. Epub 2023 Jan 2.
4
Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.接种 BNT162b2 双剂疫苗后第三剂 BNT162b2 与 ChAdOx1 对癌症患者的体液和细胞免疫对 SARS-CoV-2 的反应。
Clin Cancer Res. 2023 Feb 1;29(3):635-646. doi: 10.1158/1078-0432.CCR-22-2185.
5
Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.免疫接种三剂后和突破性 COVID-19 感染前癌症患者 SARS-CoV-2 抗体水平的定量分析。
Curr Oncol. 2022 Sep 28;29(10):7059-7071. doi: 10.3390/curroncol29100554.
6
How aging impacts vaccine efficacy: known molecular and cellular mechanisms and future directions.衰老如何影响疫苗效力:已知的分子和细胞机制及未来方向。
Trends Mol Med. 2022 Dec;28(12):1100-1111. doi: 10.1016/j.molmed.2022.09.008. Epub 2022 Oct 7.
7
Time-Varying Effect of Hybrid Immunity on the Risk of Breakthrough Infection after Booster Dose of mRNA COVID-19 Vaccine: The MOSAICO Study.mRNA新冠疫苗加强剂量后混合免疫对突破性感染风险的时变效应:MOSAICO研究
Vaccines (Basel). 2022 Aug 19;10(8):1353. doi: 10.3390/vaccines10081353.
8
Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency.在常见变异性免疫缺陷个体中,第三和第四剂 SARS-CoV-2 疫苗后的抗体反应。
Front Immunol. 2022 Jul 28;13:934476. doi: 10.3389/fimmu.2022.934476. eCollection 2022.
9
Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19.免疫功能低下的血液系统恶性肿瘤患者接种三剂 mRNA-1273 新冠疫苗后的抗体反应。
JAMA Oncol. 2022 Oct 1;8(10):1477-1483. doi: 10.1001/jamaoncol.2022.3227.
10
Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.免疫功能低下人群接种 SARS-CoV-2 疫苗后第 1、2、3 针的血清转化率:系统评价和荟萃分析。
Virol J. 2022 Aug 8;19(1):132. doi: 10.1186/s12985-022-01858-3.